Renexxion Ireland, a biopharmaceutical company, announces that the first patient has been treated in Europe with naronapride, a potential best-in-class pan-GI prokinetic, in a Phase IIb trial for gastroparesis conducted by Dr. Falk Pharma.
Article continues below
The Phase IIb trial is a multi-center, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of naronapride in patients with gastroparesis.
Study investigators will enroll and randomize approximately 300 patients to receive either naronapride at 1 of 3 doses or placebo daily for 12 weeks.
The primary endpoint of the trial is change from baseline in the signs and symptoms of either idiopathic or diabetic gastroparesis. Several additional secondary and exploratory endpoints will also be evaluated to further elucidate the efficacy and safety profile of naronapride, as compared to placebo.
Gastroparesis is a serious chronic disorder characterized by delayed gastric emptying leading to upper gastrointestinal symptoms such as nausea, vomiting or bloating.
Gastroparesis is frequently associated with significant impairment of social and occupational functioning. Despite the high-unmet medical need, there is no approved drug in this indication available.
The Phase IIb, multi-center, pan-EU clinical trial is being undertaken as part of a licensing and collaboration agreement with Dr. Falk Pharma, to evaluate the efficacy, safety and tolerability of naronapride in a cohort of subjects with gastroparesis.
The study will form part of the clinical development plan for use of naronapride in gastroparesis. Topline results for the Phase IIb trial are expected in H1, 2025.
Renexxion Ireland's lead program is naronapride, a late-stage potential best-in-class drug candidate for unmet GI indications in the upper and lower GI tract.
In scientific studies naronapride has been demonstrated to possess a unique combination of both serotonin 5HT4 receptor agonistic and dopamine D2 receptor antagonistic properties, both clinically validated targets.
Naronapride is designed to be minimally absorbable, is locally active in gut lumen, and in clinical studies its side-effect profile is indistinguishable from placebo.
Four positive Phase II studies have been completed and naronapride is Phase III ready in chronic idiopathic constipation (CIC) and gastro-esophageal reflux disease (GERD).
Naronapride has been studied in 11 clinical studies and more than 1000 subjects to date.
In these studies, naronapride has been well-tolerated with a safety profile that did not differ from the placebo-treated patients in clinical studies. Importantly, with naronapride no cardiovascular effects, including no effects on heart rate, blood pressure or ECG parameters, have been observed in clinical studies.
Gastroparesis is a digestive disorder characterized by delayed gastric emptying of solid food in the absence of mechanical obstruction of the stomach, resulting in the cardinal symptoms of early satiety, postprandial fullness, nausea, vomiting, belching and bloating.
It is now recognized as part of a broader spectrum of gastric neuromuscular dysfunction that includes impaired gastric accommodation. The total prevalent population of gastroparesis in the 7 major markets is expected to rise from 33,690,400 (2017) to 36,167,100 (2030) between 2017 and 2030. 44% of the 7 major market cases are in the European countries. ■